Acromegaly, a condition of chronic, often decades-long, pathological GH/IGF-1 excess from a pituitary tumor, is the closest real-world model for what sustained supraphysiological IGF-1 actually does to cancer incidence over time
Over 29 days of treatment, the peptide inhibited pulmonary artery muscularization (the thickening and stiffening of pulmonary arteries that drives this condition), prevented right heart hypertrophy (the enlargement of the right ventricle that occurs when it has to pump against increased resistance), and significantly decreased mortality
And then, at the level of the muscle itself, you have a built-in braking system, largely driven by myostatin, that modulates how far that growth signal can go
Available from www.who.int/mediacentre/factsheets/fs311/en/
Other areas of investigation include postmenopausal HSDD, diabetes-related sexual dysfunction, and cancer survivor sexual health